Affinity Asset Advisors’s Entera Bio ENTX Stock Holding History

Affinity Asset Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.72M	Buy	+934,412	New	+$2.5M	0.11%	104

Other funds holding ENTX

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

NEXTBio Capital Management Menlo Park, California $234M AUM 176.49% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Affinity Asset Advisors's ENTX Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Entera Bio (ENTX) in Q3 2026: 934,412 shares worth $2.72M. The stake represents 0.11% of the portfolio and ranks #104 among its holdings.

21 funds tracked by Wall St. Rank hold ENTX as of Q3 2026.

Affinity Asset Advisors held 934,412 shares of Entera Bio worth $2.72M as of Q3 2026.
Entera Bio was a new Affinity Asset Advisors position in Q3 2026.
Entera Bio made up 0.11% of Affinity Asset Advisors's portfolio in Q3 2026, its #104 holding.
21 funds tracked by Wall St. Rank held Entera Bio as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.